Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Sep 8;16(9):1372-1379.
doi: 10.1093/ecco-jcc/jjac044.

Favourable Tolerability and Drug Survival of Tioguanine Versus Methotrexate After Failure of Conventional Thiopurines in Crohn's Disease

E H J Savelkoul  1 , M H J Maas  2 , A R Bourgonje  2 , F Crouwel  3 , V B C Biemans  4 , N den Broeder  1 , M G V M Russel  5 , T E H Römkens  6 , N K de Boer  3 , G Dijkstra  2 , F Hoentjen  1   7
Affiliations
Multicenter Study

Favourable Tolerability and Drug Survival of Tioguanine Versus Methotrexate After Failure of Conventional Thiopurines in Crohn's Disease

E H J Savelkoul et al. J Crohns Colitis. .

Abstract

Background and aims: Both methotrexate and tioguanine can be considered as treatment options in patients with Crohn's disease after failure of conventional thiopurines. This study aimed to compare tolerability and drug survival of methotrexate and tioguanine therapy after failure of conventional thiopurines in patients with Crohn's disease.

Methods: We conducted a retrospective, multicentre study, including patients with Crohn's disease initiating monotherapy methotrexate or tioguanine after failure [all causes] of conventional thiopurines. Follow-up duration was 104 weeks or until treatment discontinuation. The primary outcome was cumulative therapy discontinuation incidence due to adverse events. Secondary outcomes included total number of [serious] adverse events, and ongoing monotherapy.

Results: In total, 219 patients starting either methotrexate [n = 105] or tioguanine [n = 114] were included. In all 65 [29.7%] patients (methotrexate 43.8% [46/105 people], tioguanine 16.7% [19/114 people], p <0.001) discontinued their treatment due to adverse events during follow-up. Median time until discontinuation due to adverse events was 16 weeks (interquartile range [IQR] 7-38, p = 0.812). Serious adverse events were not significantly different. Patients treated with methotrexate experienced adverse events more often [methotrexate 83%, tioguanine 46%, p <0.001]. Total monotherapy drug survival after 104 weeks was 22% for methotrexate and 46% for tioguanine [p <0.001].

Conclusions: We observed a higher cumulative discontinuation incidence due to adverse events for methotrexate [44%] compared with tioguanine [17%] in Crohn's disease patients after failure of conventional thiopurines. The total adverse events incidence during methotrexate use was higher, whereas serious adverse events incidence was similar. These favourable results for tioguanine treatment may guide the selection of immunosuppressive therapy after failure of conventional thiopurines.

Keywords: Inflammatory bowel diseases; immunosuppressives; side effects.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan–Meier survival distributions for therapy discontinuation due to adverse events. Log rank <0.001. MTX, methotrexate; TG, tioguanine.
Figure 2.
Figure 2.
Cumulative incidence of discontinuation reasons in competing risk analysis.
See this image and copyright information in PMC

References

    1. Kozarek RA, Patterson DJ, Gelfand MD, et al. . Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110[5]:353–6. Epub 1989/03/01. - PubMed
    1. Skinner MD, Schwartz RS.. Immunosuppressive therapy. 1. N Engl J Med 1972;287[5]:221–7. Epub 1972/08/03. - PubMed
    1. Jeuring SF, van den Heuvel TR, Liu LY, et al. . Improvements in the long-term outcome of Crohn’s disease over the past two decades and the relation to changes in medical management: results from the population-based IBDSL Cohort. Am J Gastroenterol 2017;112[2]:325–36. Epub 2016/12/07. - PubMed
    1. Feuerstein JD, Ho EY, Shmidt E, et al. . AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease. Gastroenterology 2021;160[7]:2496–508. Epub 2021/05/31. - PMC - PubMed
    1. Torres J, Bonovas S, Doherty G, et al. . ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis 2020;14[1]:4–22. Epub 2019/11/12. - PubMed

Publication types

MeSH terms